|
시장보고서
Molecular Targeted Cancer Therapies Market Forecast
|
Abstract
Introduction
Molecular targeted cancer therapies are the biggest and fastest growing class
of cancer drugs in terms of sales. As growth of revenues from cytotoxic
therapies and antihormonal therapies has slowed and many key brands in these
classes face imminent patent expiries, it is unsurprising that the major
oncology companies have shifted their focus towards the molecular targeted
cancer therapies market.
Key reasons to purchase this research
- Quantify the performance of each of the marketed molecular targeted cancer
therapies in the seven major markets over the period 2008 to 2018
- Assess the changing key opportunities and threats both for currently
marketed and pipeline targeted therapy cancer brands
- Identify the leading brands in this market over the next 10 years and
understand the key factors driving their success
Table of Contents
OVERVIEW
- This product contains forecasts for the molecular targeted cancer
therapies across the seven major markets from 2008 to 2018. It has been
designed for delivery in an excel data pack format, but for more detail about
this disease area please see the accompanying Commercial Insight: Molecular
Targeted Cancer Therapies (DMHC2535) word document and PowerPoint executive
presentation.
- The associated report and PowerPoint presentation can be found under
Latest research in the Knowledge centre, through the search function or by
contacting your sales representative.
- Please select the data pack option from the download menu at the side of
the page to access the model.
- Introduction
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
|
